The European Patent Office (EPO) has granted the patent EP2982381B1 “Immunogenic complex for vaccination and method for the production thereof” submitted by INMUNOTEK.
The invention relates to hypoallergenic polymerized neoglycoconjugates (allergoids-mannan) developed for the design of new anti-allergy vaccines targeting dendritic cells. This patent is in addition to those already granted by Japan, US, Mexico and China for said composition.
The conjugation of allergoids with mannan improves the bioavailability of the vaccine to dendritic cells while favoring the induction of regulatory T cells, essential to achieve the desired tolerance against the allergen.
The invention is the result of an INMUNOTEK research project that has received funding from the Center for Industrial Technological Development (CDTI, Spain) and the collaboration of researchers from the CIB-CSIC and Complutense University (Madrid).